Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with diet and exercise alone, others find that adding weight loss medications like ...

At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP-1 drugs, it targets a hormone that slows stomach emptying. Over 12 weeks, ...

The researchers working on MariTide are currently preparing for a 72-week phase 3 trial, and evaluating if the drug can help people lose more weight than the ~16% they shed in the phase II trial.

MariTide led to around 20% weight loss in obesity without diabetes vs. 2.6% with placebo. Amgen begins a 72-week Phase 3 MariTide trial, targeting obesity and comorbidities, including heart ...

These powerful weight loss and Type 2 diabetes medications are all GLP-1 drugs. MariTide is, too, but differs in that it also contains a monoclonal antibody, which helps the drug stay in the body ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Weight loss hadn't plateaued by 52 weeks, indicating patients could potentially lose more weight, Amgen said Monday. MariTide also showed sustained reduction in hemoglobin A1c. Shares fell 5% to ...

"MariTide delivered strong efficacy, including sustained weight loss without a plateau in the 52-week Phase 2 study and meaningful improvements in cardiometabolic risk factors, representing a ...